HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Differential effects of menopausal therapies on the endometrium.

AbstractOBJECTIVE:
Currently available treatments for menopausal symptoms are associated with differing endometrial safety and endometrium-related tolerability profiles. This article reviews the differential endometrial effects associated with estrogen therapy, estrogen-progestin therapy (EPT), selective estrogen receptor modulators (SERMs), and tissue-selective estrogen complex (TSEC).
METHODS:
Searches of electronic databases and of recent presentations at congresses were performed. Articles and abstracts relevant to the endometrial effects of estrogen therapy, EPT, SERMs, and TSECs were summarized in this interpretive literature review.
RESULTS:
Owing to their effects on the endometrium, cyclic and continuous-combined EPT can induce irregular uterine bleeding. Cyclic EPT may induce endometrial proliferation. Continuous-combined EPT reduces the incidence of endometrial cancer. In the endometrium, SERM activity ranges from essentially neutral to agonist, depending on the individual SERM. Raloxifene, tamoxifen, lasofoxifene, ospemifene, and bazedoxifene (BZA) demonstrated different degrees of endometrial tissue effects in preclinical and clinical studies. BZA inhibits the effects of conjugated estrogens on the endometrium. These effects are attributable to tissue-specific estrogen receptor degradation, which effectively diminishes the molecular target of estrogen activity in the endometrium. Conjugated estrogens/BZA, a TSEC, has a favorable endometrial profile, with incidences of hyperplasia and bleeding/spotting similar to those of placebo.
CONCLUSIONS:
Endometrial safety is a significant hurdle in the development of new hormone therapies for postmenopausal women. Preclinical and clinical findings suggest that BZA has an endometrial profile distinct from those of other SERMs. TSECs are a novel approach to providing relief of menopausal symptoms with adequate endometrial safety profile.
AuthorsSebastian Mirkin, David F Archer, Hugh S Taylor, James H Pickar, Barry S Komm
JournalMenopause (New York, N.Y.) (Menopause) Vol. 21 Issue 8 Pg. 899-908 (Aug 2014) ISSN: 1530-0374 [Electronic] United States
PMID24518153 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Estrogens, Conjugated (USP)
  • Selective Estrogen Receptor Modulators
Topics
  • Endometrium (drug effects)
  • Estrogen Replacement Therapy
  • Estrogens, Conjugated (USP) (administration & dosage)
  • Female
  • Hot Flashes (drug therapy)
  • Humans
  • Menopause
  • Selective Estrogen Receptor Modulators (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: